Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ariad Pharm Inc (ARIA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 4,663,416
  • Shares Outstanding, K 194,390
  • Annual Sales, $ 118,800 K
  • Annual Income, $ -231,160 K
  • 36-Month Beta 2.16
  • Price/Sales 24.94
  • Price/Cash Flow N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings -0.12 on 11/07/16
  • Next Earnings Date 02/28/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.63 +1.52%
on 01/27/17
23.99 unch
on 02/15/17
+0.30 (+1.27%)
since 01/13/17
3-Month
11.69 +105.22%
on 12/22/16
23.99 unch
on 02/15/17
+10.79 (+81.74%)
since 11/15/16
52-Week
4.67 +413.70%
on 02/24/16
23.99 unch
on 02/15/17
+19.27 (+408.26%)
since 02/12/16

Most Recent Stories

More News
ALUNBRIG(TM) (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary...

ARIA : 23.99 (+0.17%)
TKPYY : 26.0000 (-0.12%)
Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the appointment of Edward Fitzgerald to the company's board of directors. Mr. Fitzgerald, former...

ARIA : 23.99 (+0.17%)
IONS : 46.35 (-0.43%)
The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will...

MKGAY : 39.2100 (+0.13%)
ARIA : 23.99 (+0.17%)
MRK : 65.04 (+0.17%)
MDCO : 39.39 (-1.53%)
LLY : 78.34 (+0.49%)
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

--- Accretive to FY2018 Underlying Core Earnings -

ARIA : 23.99 (+0.17%)
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

STML : 8.35 (+1.21%)
ARIA : 23.99 (+0.17%)
GWPH : 108.02 (+1.61%)
GILD : 64.56 (+0.39%)
REGN : 455.70 (-0.55%)
AMGN : 155.43 (+0.54%)
BIIB : 252.97 (-0.14%)
Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan

Upcoming AWS Coverage on ARIAD Pharmaceuticals

ARIA : 23.99 (+0.17%)
TKPYY : 26.0000 (-0.12%)
EXEL : 19.57 (-2.97%)
ARIAD Pharmaceuticals Stock Sees Short Interest Decline 25.8%

The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 8,224,965 share decrease in total short interest for ARIAD Pharmaceuticals Inc , to 23,605,983, a...

ARIA : 23.99 (+0.17%)
Varian Medical (VAR) Misses on Q1 Earnings and Revenues

Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.

HOLX : 43.50 (+1.16%)
VAR : 97.72 (+1.00%)
ARIA : 23.99 (+0.17%)
GKOS : 39.92 (-0.27%)
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

HOLX : 43.50 (+1.16%)
MCK : 162.36 (+0.70%)
ARIA : 23.99 (+0.17%)
GKOS : 39.92 (-0.27%)
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance

Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate...

HOLX : 43.50 (+1.16%)
SYK : 140.85 (+0.61%)
ARIA : 23.99 (+0.17%)
GKOS : 39.92 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and...

See More

Support & Resistance

2nd Resistance Point 24.02
1st Resistance Point 24.01
Last Price 23.99
1st Support Level 23.96
2nd Support Level 23.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.